Dergiler / Balkan Medical Journal / 2020 / Cilt: 37 - Sayı: 4

Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon

Sayfa
184–188
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Therefore, we aimed to have a contributor rolefor explaining this conundrum and present a bird’s eye view regardingthis equivocal issue in this review.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:As it is known, we are all in a pandemic situation due to a novelcoronavirus, officially named “Severe Acute Respiratory SyndromeCoronavirus 2” and the disease caused by the virus named “Coronavirusdisease-2019”.
📊
Temel Bulgular & Veri:However, there isa lack of data regarding the effects of “Coronavirus disease-2019”on pediatric patients with rheumatic diseases.
💡
Sonuç & Katkı:Therefore, we aimed to have a contributor rolefor explaining this conundrum and present a bird’s eye view regardingthis equivocal issue in this review.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

As it is known, we are all in a pandemic situation due to a novelcoronavirus, officially named “Severe Acute Respiratory SyndromeCoronavirus 2” and the disease caused by the virus named “Coronavirusdisease-2019”. The virus seems to has propensity to infect older maleindividuals with underlying disease. The clinical features were on alarge scale that varies from being an asymptomatic carrier to acuterespiratory distress syndrome and multiorgan dysfunction. Fever, drycough and fatigue are the most common symptoms. Not only, thedisease seems to be rare and have a milder course in pediatric agebut also respiratory failure, multiorgan dysfunction, and death areextremely rare. Although several comorbidities such as hypertension,diabetes and cardiovascular diseases are defined as a risk factor fordeveloping the acute respiratory syndrome and need for intensivecare; immune-compromised situations such as rheumatic diseasewhich require immunosuppressive treatment strikingly are not foundto be a risk factor for more severe disease course. However, there isa lack of data regarding the effects of “Coronavirus disease-2019”on pediatric patients with rheumatic diseases. Additionally, thereare three controversial circumstances that patients with rheumaticdiseases are believed to be more likely to have viral infections like“Severe Acute Respiratory Syndrome Coronavirus 2”, on the otherhand, antirheumatic drugs may have a protective and therapeutic rolein Coronavirus disease-2019 and children are more unlikely to haveserious disease course. Therefore, we aimed to have a contributor rolefor explaining this conundrum and present a bird’s eye view regardingthis equivocal issue in this review.

🔖

Bu Makaleye Atıf Yap

BARUT, K., YILDIZ, M., HAŞLAK, F., KASAPÇOPUR, Ö., ADROVIC, A. (2022). Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon. Balkan Medical Journal, Cilt: 37 - Sayı: 4, 184–188. https://ajindex.com/articles/460931

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Report of clustering pneumonia of unknown etiology in Wuhan City. Wuhan Municipal Health Commission; 2019. http://wjw.wuhan.gov.cn/front/web/ showDetail/2019123108989 Accessed on April 3, 2020
  2. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020;87:281-6
  3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506
  4. She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. J Med Virol 2020 Mar 31. doi: 10.1002/jmv.25807. [Epub ahead of print] 5. Organization WH. Coronavirus disease 2019 (COVID-19): situation report, 51. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311- sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10 Accessed on April 3, 2020
  5. Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 2020;38:337-42
  6. Wang Q, Qi J, Yuan Y, Xuan Y, Han P, Wan Y, et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe 2014;16:328-37
  7. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3
  8. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002;532:107-10
  9. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmum 2020:102433. 11. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14:523-34
  10. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586-90
  11. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020:102523
  12. Wang W, He J, Lie P, Huang L, Wu S, Lin Y, et al. The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis. Medrxiv February 27, 2020. doi: https://doi.org/10.